BDF Gestion Sells 6,996 Shares of AbbVie Inc. (NYSE:ABBV)

BDF Gestion lessened its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 11.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 53,861 shares of the company's stock after selling 6,996 shares during the quarter. AbbVie comprises approximately 0.9% of BDF Gestion's holdings, making the stock its 19th largest position. BDF Gestion's holdings in AbbVie were worth $9,571,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Groupama Asset Managment grew its holdings in AbbVie by 40.3% in the 3rd quarter. Groupama Asset Managment now owns 135,749 shares of the company's stock valued at $27,000 after buying an additional 38,974 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of AbbVie in the third quarter valued at approximately $28,000. Retirement Wealth Solutions LLC acquired a new stake in shares of AbbVie in the fourth quarter worth $35,000. Marquette Asset Management LLC bought a new position in AbbVie during the third quarter worth $39,000. Finally, Mizuho Securities Co. Ltd. raised its stake in AbbVie by 100.0% during the 3rd quarter. Mizuho Securities Co. Ltd. now owns 200 shares of the company's stock valued at $39,000 after purchasing an additional 100 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares of the company's stock, valued at approximately $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.25% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ABBV shares. Truist Financial dropped their price objective on shares of AbbVie from $215.00 to $211.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Wells Fargo & Company upped their price target on AbbVie to $195.00 and gave the company a "buy" rating in a report on Tuesday, November 19th. UBS Group lifted their price objective on AbbVie from $195.00 to $200.00 and gave the stock a "neutral" rating in a report on Thursday, October 31st. Morgan Stanley cut their target price on AbbVie from $231.00 to $224.00 and set an "overweight" rating for the company in a research note on Tuesday, November 12th. Finally, BMO Capital Markets lowered their price target on shares of AbbVie from $228.00 to $208.00 and set an "outperform" rating on the stock in a report on Tuesday, November 12th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $205.00.

AbbVie Trading Up 0.2 %

ABBV traded up $0.28 during mid-day trading on Thursday, reaching $175.54. The stock had a trading volume of 5,202,830 shares, compared to its average volume of 5,918,073. The stock has a market capitalization of $310.21 billion, a P/E ratio of 60.95, a P/E/G ratio of 1.68 and a beta of 0.58. AbbVie Inc. has a 52 week low of $153.58 and a 52 week high of $207.32. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The firm's fifty day simple moving average is $176.37 and its two-hundred day simple moving average is $184.90.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.92 by $0.08. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business had revenue of $14.46 billion for the quarter, compared to analysts' expectations of $14.28 billion. During the same quarter last year, the business earned $2.95 earnings per share. The firm's quarterly revenue was up 3.8% compared to the same quarter last year. On average, equities analysts predict that AbbVie Inc. will post 10.06 EPS for the current year.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.